glp-1 made from lizards to lifelines 1348: "Ozempic Venom" — JC
Description
Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss
Originally developed to treat type 2 diabetes (T2D), these drugs have since delivered major advances in managing obesity and cardiovascular risk reduction
Metseras pipeline includes MET-097i, a GLP-1 receptor agonist designed for once-monthly dosing, and MET-233i, an amylin analog being developed for monthly administration
Goldman Sachs forecasts that the global weight-loss drug market will reach USD 114 billion by 2030, an upward revision of 13% from last years estimate
GLP-1 has transformed the approach to weight loss, and some people using it notice an increase in hair loss, which can be concerning.
CareSource []
